Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]Oxaliplatin Microdosing for Chemoresistance Prediction in Breast Cancer
NCT02077998Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- May 2015
- Primary completion
- May 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin in breast cancer, sponsored by University of California, Davis. Primary endpoint: Threshold at which oxaliplatin-DNA adducts predict response to therapy. Started May 2015; status: completed.
02
Drugs
oxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02077998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077998.